{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:26:52Z","timestamp":1792610812068,"version":"4.5.0"},"reference-count":106,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Annals of Medicine"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/07853890.2022.2085881","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T06:52:49Z","timestamp":1655707969000},"page":"1686-1700","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":151,"title":["Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance"],"prefix":"10.1080","volume":"54","author":[{"given":"Kerry L.","family":"LaPlante","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Rhode Island","place":["Kingston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Dhand","sequence":"additional","affiliation":[{"name":"Westchester Medical Center, New York Medical College","place":["Valhalla, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Wright","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lauterio","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistant threats in the United States; 2019. https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html."},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1581"},{"issue":"8","key":"e_1_3_4_4_1","first-page":"1686","article-title":"The 10 x '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020","volume":"50","year":"2010","unstructured":"The 10 x '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50(8):1686\u20131083.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz089"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00594-16"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/367622"},{"key":"e_1_3_4_9_1","unstructured":"Pharma AA. Tetracycline (tetracycline hydrochloride) prescribing information. 2010. https:\/\/www.aapharma.ca\/downloads\/en\/PIL\/Tetracycline_PI.pdf."},{"key":"e_1_3_4_10_1","unstructured":"Paratek Pharmaceuticals. Nuyzra(R) (omadacycline) prescribing information. 2020. https:\/\/www.nuzyra.com\/nuzyra-pi.pdf."},{"key":"e_1_3_4_11_1","unstructured":"Pfizer. TYGACIL\u00ae (tigecycline) prescribing information. 2005. https:\/\/www.pfizermedicalinformation.com\/en-us\/tygacil."},{"key":"e_1_3_4_12_1","unstructured":"Apotex Inc. Doxycycline hyclate prescribing information. 2016. https:\/\/pdf.hres.ca\/dpd_pm\/00037247.PDF."},{"key":"e_1_3_4_13_1","unstructured":"Tetraphase Pharmaceuticals. XERAVA (eravacycline) prescribing information. 2020. https:\/\/www.tphase.com\/products\/xerava\/."},{"key":"e_1_3_4_14_1","unstructured":"Valeant Pharmaceuticals. MINOCIN\u00ae (minocycline hydrochloride) prescribing information. 2019. https:\/\/www.fda.gov\/media\/121327\/download."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.43.7.860"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4893.914"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(69)91799-1"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg208"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01058"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025387"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202000014"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.66.11.4615-4619.2000"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2003.15.1.12"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.8.1732"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy270"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab063"},{"key":"e_1_3_4_27_1","unstructured":"Huband MD Pfaller MA Streit JM et\u00a0al. Activity of omadacycline against 7 000 bacterial isolates from the United States in the SENTRY Antimicrobial Surveillance Program (2020). World Microbe Forum 2021. June 20\u201324."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.023"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.022"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2013-0292"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.738"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/598510"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115054"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10020165"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1793"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1103"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02465-15"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.09.005"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00916"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0445-2"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0496-4"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-015-0085-1"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.220-229.2005"},{"key":"e_1_3_4_46_1","unstructured":"Center for Drug Evaluation and Research. Eravacycline multi-discipline review; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211109Orig1s000MultidisciplineR.pdf."},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00250-17"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S171352"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00058-2.x"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.07.029"},{"key":"e_1_3_4_52_1","unstructured":"Center for Drug Evaluation and Research. Xerava (eravacycline): NDA multidisciplinary review and evaluation 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211109Orig1s000MultidisciplineR.pdf."},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01046-07"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz309"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-19"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02368-16"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00647-08"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa558"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.09.001"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-9-44"},{"key":"e_1_3_4_62_1","unstructured":"US Department of Health and Human Services FaDA Center for Drug Evaluation and Research (CDER). Guidance for Industry. Community-acquired bacterial pneumonia: developing drugs for treatment; 2014. http:\/\/www.fda.gov\/media\/75149\/download."},{"key":"e_1_3_4_63_1","unstructured":"US Department of Health and Human Services FaDA Center for Drug Evaluation and Research (CDER). Guidance for Industry. Acute bacterial skin and skin structure infections: developing drugs for treatment; 2013. http:\/\/www.fda.gov\/media\/71052\/download."},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4658-4666.2005"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2005.05.003"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2005.03.011"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-5-88"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12265336"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02176-12"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt477"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt129"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix833"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03756-z"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz398"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00351-0"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01581-18"},{"key":"e_1_3_4_81_1","article-title":"Omadacycline and Clostridioides difficile: a systematic review of preclinical and clinical evidence","author":"Garey KW","unstructured":"Garey KW, Rose W, Gunter K, et\u00a0al. Omadacycline and Clostridioides difficile: a systematic review of preclinical and clinical evidence. Ann Med.","journal-title":"Ann Med"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.12.007"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku062"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-13"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2181"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa548"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106442"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt299"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.104018"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0520-9"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/13814780701815116"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw462"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.4234"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12046"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2015.239"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.13.47.19044-en"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1451"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.02.009"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01257-4"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-020-02019-8"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz395"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S44646"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02488-19"},{"issue":"3","key":"e_1_3_4_105_1","first-page":"e01715","article-title":"In vitro activity of eravacycline against gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey I","year":"2020","unstructured":"Morrissey I, Hawser S, Lob SH, et\u00a0al. In vitro activity of eravacycline against gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2020;64(3):e01715\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04354-14"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7159.657"}],"container-title":["Annals of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/07853890.2022.2085881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:47:47Z","timestamp":1757324867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/07853890.2022.2085881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/07853890.2022.2085881"],"URL":"https:\/\/doi.org\/10.1080\/07853890.2022.2085881","relation":{},"ISSN":["0785-3890","1365-2060"],"issn-type":[{"value":"0785-3890","type":"print"},{"value":"1365-2060","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iann20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iann20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}